Novartis gets rights to hepatitis C therapy

Tuesday 9 February 2010

Novartis AG has in-licensed a new compound for the treatment of hepatitis C that is described as the first in a new class of drugs called cyclophilin inhibitors. The deal was announced on 9 February, 2010 but no financial details were disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland